Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Hepatitis C Condition: Genotypes 1, 4, 5, or 6 |
Dose: Subcutaneous injection – 1.5 mcg/kg Frequency: once weekly Duration: 12 weeks (treatment-naive or relapsed); may extend to 24 weeks for nonresponders Note: Not to exceed 150 mcg/week; part of preferred regimen PLUS Ribavirin by mouth 1000-1200 mg/day plus sofosbuvir 400 mg by mouth once daily; Peginterferon is not recommended as monotherapy for any patient group |
|
Indication: Chronic Hepatitis C Condition: Genotype 1 |
Dose: Tablet – Simeprevir 150 mg/day plus Peginterferon/Ribavirin Duration: Simeprevir for 12 weeks plus Peginterferon/Ribavirin for 24 weeks Note: Alternative regimen |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Hepatitis C Age: less than 3 years |
Dose: Subcutaneous Injection – Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Chronic Hepatitis C Age: 3-17 years |
Dose: Subcutaneous Injection – 60 mcg/m² Frequency: once weekly Note: administered with ribavirin 15 mg/kg/day by mouth divided every 12 hours; administer on same day each week |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: chronic hepatitis C Condition: moderate renal impairment (CrCl 30-50 mL/min) |
Dose: alpha interferons Note: Reduce dose by 25% |
|
Indication: chronic hepatitis C Condition: severe renal impairment (CrCl 10-29 mL/min, including hemodialysis) |
Dose: alpha interferons Note: Reduce dose by 50% |
Administration
- Inject subcutaneously once weekly
- Rotate injection sites
Side Effect
- Headache (56%)
- Fatigue (52%)
- Injection site inflammation/reaction (47%)
- Depression (16-29%)
- Anxiety/emotional lability/irritability (28%)
- Nausea (26%)
- Insomnia (23%)
- Alopecia (22%)
- Fever (22%)
- Anorexia (20%)
- Diarrhea (18%)
- Abdominal pain (15%)
- Dizziness (12%)
- Impaired concentration (5-12%)
- Pain (12%)
- Pruritus (12%)
- Dry skin (11%)
- Weight loss (11%)
- Pharyngitis (10%)
- Transient increase in transaminases (10%)
- Malaise (8%)
- Dermatitis (7%)
- Sinusitis (7%)
- Vomiting (7%)
- Dyspepsia (6%)
- Flushing (6%)
- Hepatomegaly (6%)
- Rash (6%)
- Hypertonia (5%)
- Hypothyroidism (5%)
- Injection site pain (2%)
- Taste perversion
- Neutropenia
- Thrombocytopenia
- Colitis
- Pancreatitis
- Autoimmune thrombocytopenia
- Blindess
- thrombosis of retinal vein
- Aggressive behavior
- Depression
- Homicidal thoughts
- suicidal thoughts
- suicide
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Ribavirin
|
Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic
|
|
Theophylline
|
Decreases metabolism
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Autoimmune hepatitis
|
May worsen liver condition
|
|
Decompensated liver disease
|
Risk of liver failure
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.